Drug Trial Radar · NCT02092116
Safety and Efficacy of Romidepsin and the Therapeutic Vaccine Vacc-4x for Reduction of the Latent HIV-1 Reservoir
Last checked: Nov 19, 2026Latest source record: Mar 1, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
26
Actual
Start
Mar 2014
Primary completion
Aug 2015
Study completion Dec 2015
Sponsor
- Lead sponsor
- Bionor Immuno ASIndustry
- Sponsor type
- Industry
- Collaborators
- Celgene Corporation
- First posted
- Mar 19, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The REDUC trial's objective is to address one of the core issues with the treatment of HIV, which is that some HIV infected cells hide in so-called latent reservoirs. The reservoirs are unaffected by conventional HIV medication and invisible to the immune system. HDACi have the potential to activate these latently infected cells. This will make the HIV infected cells visible to the immune system; the immune response generate by Vacc-4x will be able to attack and eliminate the infected cells.
Conditions
- HIV I Infection
Interventions
RomidepsinDrug
Latency reversing agent
Vacc-4xBiological
Vacc-4x is a peptide-based HIV immunotherapy administered intradermally. Vacc-4x peptides are reconstituted in sterile water.
rhuGM-CSFBiological
Granulocyte macrophage colony stimulating factor as a local adjuvant
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)Time frame: 3 weeks
- Part B: Changes From Baseline in HIV-1 Reservoir (Total HIV-1DNA; Integrated HIV-1 DNA in Unfractionated CD4+ T Cells and Replication Competent Provirus.Time frame: Day 161/175
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Aarhus University Hospital, Skejby Sygehus
Aarhus N, Denmark
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.